Congratulations to Our New PhD Graduates: Jiafeng Zhong, Buwei Hu and Xuehan Xu!
[Chengdu, China | Aug 27-29, 2026] Members of our research group, Tingting Cao, Zhanqing Jin and Zheyan Xu attended The 6th International Conference on Nanomedicine. The current conference, themed "Nanomedicine: Innovation for Advancing Health," aims to establish a high-level academic exchange platform for fundamental research, clinical translation, and industrial applications of nanomedicines.
[Hangzhou, China | Aug 6, 2026] Our research group recently organized a team‑building activity to welcome a cohort of undergraduate students who have joined us for a month‑long summer research internship. The interns come from several institutions, including the University of Santiago de Compostela (Spain), the University of Texas at Austin (USA), Capital Medical University (China), and other partner universities. The casual gathering fostered cross‑cultural exchange and helped build a collaborative spirit for the intensive research.
[Hangzhou, China | May 30, 2026] Prof. Jinpeng Sun (Shandong University & Peking University) presented a seminar titled "Discovery and Functional Studies of Membrane Receptors for Steroid Hormones, Ceramides, and Balance Sensation" at Yungu Campus. The event was co-hosted by Prof. Jianjun Cheng and Prof. Zibo Chen. Sun shared his team’s breakthroughs in GPCR biology, including new receptors for hormones and lipids, as well as mechanoreceptors for balance and hearing. Faculty and students from across the university attended and engaged in lively discussion.
[Linzhi, China | May 22-24, 2026] Members of our research group attended the New Cornerstone Investigator Conference (Spring 2026). During the conference, Assistant Researcher Yaofeng Zhou delivered a flash report, sharing key insights and preliminary findings from the group’s ongoing research.
[Beijing, China | May 10-13, 2026] Members of our research group attended The 9th China-Europe Symposium on Biomaterials in Regenerative Medicine (CESB 2026). Prof. Cheng delivered a Keynote Lecture titled “Development of Covalent Targeting Therapeutics Based on In Vivo Click Chemistry”.
[Hangzhou, May 6th, 2026] Hangzhou Surio Therapeutics Co., Ltd. (“Surio”), a biopharmaceutical company dedicated to developing first-in-class therapies to address unmet medical needs in oncology, today announced the successful completion of the Phase Ia clinical study for its investigational drug, SURIO-001. The trial, conducted by its subsidiary Avisure, evaluated the drug in healthy subjects. The study results demonstrated that the ST114 molecule in the SURIO-001 combination exhibited a favorable safety and tolerability profile in healthy subjects with no grade 2 or higher adverse event. Predefined pharmacokinetic objectives were also achieved. These data provide a robust foundation for subsequent clinical investigation in cancer patients. Based on the positive safety and tolerability results from the Phase Ia study, the company will initiate the Phase Ib clinical trial of the drug very soon.
Members of our research group attended The 35th CCS Congress, Zhen Yuan delivered a Flash Report and shared her work about Synthesis and Applications of Supra-Natural β-Sheet-Based Polypeptides.
Recently, Cao Tingting, a Ph.D. student in Professor Cheng Jianjun’s lab at the School of Engineering, Westlake University, was selected for the “2026 Excellence in Graduate Polymer Research Symposium” and invited to present a poster. She is also the only Ph.D. student from a Chinese university among the 36 selected participants worldwide this year.
[March 26th, 2026] The inaugural AbbVie China Innovation Award results were officially announced at the 2026 AbbVie China Partnering Day. Surio Therapeutics successfully won the only award in the therapeutics area for its first-in-class ATTACK technology. The award was announced by Dr. Cathy Xiao, Development Head, AbbVie China, and Dr. Christian R. Schubert, Vice President and Head of AbbVie Ventures. Dr. Kaimin Cai, Co-founder and Chief Technology Officer of Surio Therapeutics, received the award on behalf of the company. This recognition signifies professional appreciation from a globally prestigious biopharma regarding Surio Therapeutics' leading technology.
DNA-based neural networks are emerging as a biocompatible and energy-saving computing paradigm, but they have long been constrained by the lack of hardware reusability. In this work, we establish an unprecedented noncomplementary DNA-based neural network that relies exclusively on reversible strand-displacement reactions, providing an inherently reusable computing framework capable of multibit ...
Hangzhou, China, September, 9th, 2025, Surio Therapeutics Co. Ltd announces IND clearance for first-in-class targeted cancer therapeutics SURIO-001 from Center for Drug Evaluation (CDE), NMPA, China. Surio will initiate Phase I clinical trial in China soon
Address：No. 600 Dunyu Road, Sandun Town, Xihu District 310030 Hangzhou, Zhejiang PR China
Email: chengjianjun@westlake.edu.cn (research affairs)
chenglab_hire@westlake.edu.cn (admissions & recruitment affairs)
